GlassScriptPhysician profile
Evan Wu
NPI 1891149126
$113,896.90
in general payments reported to CMS, 2019-2025
29 companies · $60K in 2025
The $60K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $160 · 2022: $733 · 2023: $11K · 2024: $42K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $33K · Travel and Lodging: $11K · Food and Beverage: $3,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,692.50 |
| Consulting Fee | $33,227.25 |
| Travel and Lodging | $11,389.84 |
| Food and Beverage | $3,694.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $42,810.93 | 2023-2025 | Rybrevant, Carvykti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27,422.03 | 2025 | |
| Jazz Pharmaceuticals INC. | $12,876.77 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,218.00 | 2023-2024 | Alunbrig, Exkivity, Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $4,428.19 | 2022-2024 | Tagrisso, Enhertu |
| Amgen INC. | $4,196.51 | 2020-2025 | Imdelltra (Amg757), Imdelltra (Amg 757), Lumakras |
| E.R. Squibb & Sons, L.L.C. | $2,921.56 | 2020-2024 | Opdivo |
| Abbvie INC. | $2,400.00 | 2024 | |
| Daiichi Sankyo INC. | $2,346.49 | 2020-2025 | Enhertu, Datroway |
| Springworks Therapeutics, INC. | $2,198.12 | 2024-2025 | Ogsiveo |
| Fosun Pharma USA INC. | $2,002.76 | 2023-2025 | Serplulimab |
| Janssen Scientific Affairs, LLC | $1,949.62 | 2024-2025 | Rybrevant |
| Genentech USA, INC. | $1,070.00 | 2025 | Tecentriq |
| Novocure INC. | $224.00 | 2022-2023 | Optune |
| Aveo Pharmaceuticals, INC. | $205.39 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $120.03 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $98.95 | 2022 | |
| Genzyme Corporation | $92.43 | 2022-2023 | |
| Gilead Sciences, INC. | $67.62 | 2025 | |
| Merck Sharp & Dohme LLC | $53.74 | 2022-2023 | Keytruda |
| Pfizer INC. | $41.33 | 2020-2025 | |
| Astellas Pharma US INC | $30.54 | 2023-2025 | Xospata, Vyloy |
| Rigel Pharmaceuticals, INC. | $27.27 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Puma Biotechnology, INC. | $19.54 | 2020 | |
| Lilly USA, LLC | $18.95 | 2020 | |
| Kyowa Kirin, INC. | $16.20 | 2023 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $14.63 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.58 | 2020 | |
| Karyopharm Therapeutics INC. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.